Skip to contentVisit Welcome to CAR-T & Cellular Therapy Focus, where you can explore the latest updates in this field by haematological disease and therapy type, showcasing expert interviews and discussions, podcasts and e-learning.CAR-T and other cellular therapies are at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Although…
Alex Rampotas, MD, University College London, London, UK, summarizes a talk on the role of donor lymphocyte infusion (DLI) in the post-allogenic stem cell transplant…
Rémy Duléry, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the main side effects associated with post-transplant cyclophosphamide (PTCy) as prophylaxis for graft-versus-host disease (GvHD) following…
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients…
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, discusses promising combination approaches for overcoming venetoclax resistance in acute myeloid leukemia (AML). He mentions…
Thomas Fox, MbChB, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses CRISPR-based autologous gene therapy for treating primary immunodeficiency disorders (PIDs).…
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients…
Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon, summarizes a talk on the current standard of care, outcomes, and unmet…
VJHemOnc is excited to share an exclusive case study exploring the current approach to the diagnosis and classification of follicular lymphoma.
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients…
